好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effect of Standardized Neurologic and Psychiatric Evaluation on Prognosis for Patients Diagnosed with Functional Seizures in the Epilepsy Monitoring Unit: A Quality Improvement Initiative
Epilepsy/Clinical Neurophysiology (EEG)
P6 - Poster Session 6 (8:00 AM-9:00 AM)
1-015

To implement a standardized approach to the initial management of functional seizures (FS)/psychogenic non-epileptic events (PNEE) in the Epilepsy Monitoring Unit (EMU).

FS/PNEE is a functional neurological disorder characterized by events resembling epileptic seizures without electrographic correlate, representing up to 40% of diagnoses in the EMU.  The initial stage after diagnosis may represent a critical period that can affect long-term prognosis.  We implemented a standardized approach to disclosing diagnosis and coordinating psychological intervention in newly diagnosed FS/PNEE.

We followed patients diagnosed with FS/PNEE in the EMU at the Hospital of the University of Pennsylvania. The pre-intervention group (n = 17, admitted May-November 2022) received care according to standard practice. The post-intervention group (n = 24, admitted November 2022-May 2023) received (1) standardized disclosure of diagnosis, (2) inpatient psychiatry consult, and (3) follow-up phone call to coordinate outpatient psychology visit. Primary outcome was reduction in event frequency measured at a three-month neurology follow-up visit.

Among patients who attended the neurology follow-up visit (66%), event frequency significantly decreased after EMU admission in both groups (overall, pre-EMU median (IQR): 30.0 (4.0-30.0) events/month, post-EMU: 3.5 (1.0-10.0), T+ = 173.5, p = 0.002). There was no difference in reduction in event frequency between the pre- and post-intervention groups (p = 0.96). Half of patients in the post-intervention group had not scheduled psychology follow-up by the time of their neurology visit. Reasons cited for lack of psychology follow up included (1) Did not know how to arrange, (2) Insurance/financial issues, and (3) Long wait time.

Patients with FS/PNEE have fewer events after their diagnosis is disclosed in the EMU. There was no clear benefit from a standardized approach to disclosing diagnosis and coordinating psychological intervention. Limitations include sample size, loss to follow-up, and interval of follow-up. 

Authors/Disclosures
Kelly A. Boylan, MD
PRESENTER
Dr. Boylan has nothing to disclose.
Jennifer Jolivert No disclosure on file
Grace Wu No disclosure on file
Eleanor Anderson (HUP Psychiatry) No disclosure on file
Kathryn A. Davis, MD (University of Pennsylvania) Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW Pharmaceuticals/Jazz Pharmaceuticals. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UNEEG. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. Dr. Davis has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Pfizer. The institution of Dr. Davis has received research support from Eisai. The institution of Dr. Davis has received research support from Liminal. Dr. Davis has received publishing royalties from a publication relating to health care.
Michael Gelfand, MD, PhD (University of Pennsylvania) Dr. Gelfand has received personal compensation in the range of $0-$499 for serving as a Consultant for Aquestive. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Livanova. The institution of Dr. Gelfand has received research support from Aquestive. The institution of Dr. Gelfand has received research support from Xenon. The institution of Dr. Gelfand has received research support from Cerevel. The institution of Dr. Gelfand has received research support from UNEEG. The institution of Dr. Gelfand has received research support from Livanova. The institution of Dr. Gelfand has received research support from UCB. The institution of Dr. Gelfand has received research support from SK Pharma. The institution of Dr. Gelfand has received research support from Otsuka.
Erin C. Conrad, MD (University of Pennsylvania) Dr. Conrad has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epiminder. Dr. Conrad has stock in Humana. Dr. Conrad has stock in Lilly Eli. Dr. Conrad has stock in Medtronic. Dr. Conrad has stock in Merck. Dr. Conrad has stock in Nevro. Dr. Conrad has stock in Sanofi. Dr. Conrad has stock in United Health Group.